nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—ABCG2—epilepsy syndrome	0.0915	0.31	CbGaD
Gefitinib—CYP2C19—epilepsy syndrome	0.072	0.244	CbGaD
Gefitinib—CYP2D6—epilepsy syndrome	0.0534	0.181	CbGaD
Gefitinib—ALB—epilepsy syndrome	0.0399	0.135	CbGaD
Gefitinib—ABCB1—epilepsy syndrome	0.0381	0.129	CbGaD
Gefitinib—ALB—Oxcarbazepine—epilepsy syndrome	0.0165	0.0403	CbGbCtD
Gefitinib—ALB—Fosphenytoin—epilepsy syndrome	0.0144	0.0352	CbGbCtD
Gefitinib—CYP3A5—Oxcarbazepine—epilepsy syndrome	0.0133	0.0324	CbGbCtD
Gefitinib—ALB—Clonazepam—epilepsy syndrome	0.0131	0.0319	CbGbCtD
Gefitinib—CYP1A1—Propofol—epilepsy syndrome	0.0116	0.0284	CbGbCtD
Gefitinib—CYP1A1—Phenobarbital—epilepsy syndrome	0.0111	0.0271	CbGbCtD
Gefitinib—CYP2C19—Oxcarbazepine—epilepsy syndrome	0.0107	0.0261	CbGbCtD
Gefitinib—ALB—Rufinamide—epilepsy syndrome	0.0106	0.026	CbGbCtD
Gefitinib—CYP2C19—Trimethadione—epilepsy syndrome	0.00996	0.0243	CbGbCtD
Gefitinib—CYP2C19—Felbamate—epilepsy syndrome	0.00996	0.0243	CbGbCtD
Gefitinib—ABCB1—Levetiracetam—epilepsy syndrome	0.00945	0.0231	CbGbCtD
Gefitinib—CYP2C19—Fosphenytoin—epilepsy syndrome	0.00936	0.0228	CbGbCtD
Gefitinib—ALB—Phenytoin—epilepsy syndrome	0.0093	0.0227	CbGbCtD
Gefitinib—ALB—Propofol—epilepsy syndrome	0.00868	0.0212	CbGbCtD
Gefitinib—CYP3A5—Carbamazepine—epilepsy syndrome	0.00834	0.0203	CbGbCtD
Gefitinib—CYP2C9—Trimethadione—epilepsy syndrome	0.00828	0.0202	CbGbCtD
Gefitinib—CYP2C19—Clobazam—epilepsy syndrome	0.00812	0.0198	CbGbCtD
Gefitinib—ALB—Diazepam—epilepsy syndrome	0.00786	0.0192	CbGbCtD
Gefitinib—CYP2C9—Fosphenytoin—epilepsy syndrome	0.00778	0.019	CbGbCtD
Gefitinib—CYP3A5—Phenytoin—epilepsy syndrome	0.00748	0.0182	CbGbCtD
Gefitinib—CYP2C19—Carbamazepine—epilepsy syndrome	0.00673	0.0164	CbGbCtD
Gefitinib—CYP3A5—Phenobarbital—epilepsy syndrome	0.00667	0.0163	CbGbCtD
Gefitinib—CYP3A5—Midazolam—epilepsy syndrome	0.00657	0.016	CbGbCtD
Gefitinib—ABCB1—Clobazam—epilepsy syndrome	0.00655	0.016	CbGbCtD
Gefitinib—CYP3A5—Diazepam—epilepsy syndrome	0.00632	0.0154	CbGbCtD
Gefitinib—ABCB1—Lamotrigine—epilepsy syndrome	0.0063	0.0154	CbGbCtD
Gefitinib—CYP2C19—Primidone—epilepsy syndrome	0.00628	0.0153	CbGbCtD
Gefitinib—CYP2C19—Phenytoin—epilepsy syndrome	0.00603	0.0147	CbGbCtD
Gefitinib—CYP2C19—Propofol—epilepsy syndrome	0.00563	0.0137	CbGbCtD
Gefitinib—CYP2C9—Carbamazepine—epilepsy syndrome	0.00559	0.0136	CbGbCtD
Gefitinib—ABCB1—Carbamazepine—epilepsy syndrome	0.00543	0.0132	CbGbCtD
Gefitinib—CYP2C19—Phenobarbital—epilepsy syndrome	0.00538	0.0131	CbGbCtD
Gefitinib—CYP2C9—Primidone—epilepsy syndrome	0.00522	0.0127	CbGbCtD
Gefitinib—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.00518	0.0126	CbGbCtD
Gefitinib—CYP2C19—Diazepam—epilepsy syndrome	0.0051	0.0124	CbGbCtD
Gefitinib—CYP2C9—Phenytoin—epilepsy syndrome	0.00502	0.0122	CbGbCtD
Gefitinib—CYP3A5—Valproic Acid—epilepsy syndrome	0.00498	0.0122	CbGbCtD
Gefitinib—CYP2C19—Zonisamide—epilepsy syndrome	0.00497	0.0121	CbGbCtD
Gefitinib—ABCB1—Phenytoin—epilepsy syndrome	0.00487	0.0119	CbGbCtD
Gefitinib—CYP3A4—Felbamate—epilepsy syndrome	0.00481	0.0117	CbGbCtD
Gefitinib—CYP3A4—Trimethadione—epilepsy syndrome	0.00481	0.0117	CbGbCtD
Gefitinib—CYP2C9—Propofol—epilepsy syndrome	0.00468	0.0114	CbGbCtD
Gefitinib—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00453	0.011	CbGbCtD
Gefitinib—CYP2C9—Phenobarbital—epilepsy syndrome	0.00447	0.0109	CbGbCtD
Gefitinib—ABCB1—Phenobarbital—epilepsy syndrome	0.00434	0.0106	CbGbCtD
Gefitinib—ABCB1—Midazolam—epilepsy syndrome	0.00428	0.0104	CbGbCtD
Gefitinib—CYP2D6—Propofol—epilepsy syndrome	0.00428	0.0104	CbGbCtD
Gefitinib—CYP2C9—Diazepam—epilepsy syndrome	0.00424	0.0103	CbGbCtD
Gefitinib—ABCB1—Diazepam—epilepsy syndrome	0.00411	0.01	CbGbCtD
Gefitinib—CYP3A4—Clonazepam—epilepsy syndrome	0.00409	0.00999	CbGbCtD
Gefitinib—CYP2C19—Valproic Acid—epilepsy syndrome	0.00402	0.0098	CbGbCtD
Gefitinib—CYP3A4—Clobazam—epilepsy syndrome	0.00392	0.00957	CbGbCtD
Gefitinib—CYP2C19—Topiramate—epilepsy syndrome	0.00363	0.00885	CbGbCtD
Gefitinib—CYP2C9—Valproic Acid—epilepsy syndrome	0.00334	0.00815	CbGbCtD
Gefitinib—CYP3A4—Rufinamide—epilepsy syndrome	0.00334	0.00814	CbGbCtD
Gefitinib—CYP3A4—Carbamazepine—epilepsy syndrome	0.00325	0.00793	CbGbCtD
Gefitinib—CYP3A4—Primidone—epilepsy syndrome	0.00304	0.00741	CbGbCtD
Gefitinib—CYP3A4—Phenytoin—epilepsy syndrome	0.00292	0.00712	CbGbCtD
Gefitinib—CYP3A4—Propofol—epilepsy syndrome	0.00272	0.00664	CbGbCtD
Gefitinib—CYP3A4—Acetazolamide—epilepsy syndrome	0.0026	0.00634	CbGbCtD
Gefitinib—CYP3A4—Phenobarbital—epilepsy syndrome	0.0026	0.00634	CbGbCtD
Gefitinib—CYP3A4—Midazolam—epilepsy syndrome	0.00256	0.00625	CbGbCtD
Gefitinib—CYP3A4—Diazepam—epilepsy syndrome	0.00246	0.00601	CbGbCtD
Gefitinib—CYP3A4—Zonisamide—epilepsy syndrome	0.00241	0.00587	CbGbCtD
Gefitinib—CYP3A4—Valproic Acid—epilepsy syndrome	0.00194	0.00474	CbGbCtD
Gefitinib—CYP3A4—Topiramate—epilepsy syndrome	0.00175	0.00428	CbGbCtD
Gefitinib—ERBB3—Bortezomib—Lacosamide—epilepsy syndrome	0.00115	1	CbGdCrCtD
Gefitinib—SBK1—medulla oblongata—epilepsy syndrome	0.000967	0.023	CbGeAlD
Gefitinib—MAP2K5—hindbrain—epilepsy syndrome	0.000891	0.0211	CbGeAlD
Gefitinib—SBK1—midbrain—epilepsy syndrome	0.000884	0.021	CbGeAlD
Gefitinib—SBK1—spinal cord—epilepsy syndrome	0.000863	0.0205	CbGeAlD
Gefitinib—SBK1—head—epilepsy syndrome	0.000767	0.0182	CbGeAlD
Gefitinib—CSNK1E—forebrain—epilepsy syndrome	0.00074	0.0176	CbGeAlD
Gefitinib—ERBB3—forebrain—epilepsy syndrome	0.000714	0.0169	CbGeAlD
Gefitinib—EGFR—telencephalon—epilepsy syndrome	0.000707	0.0168	CbGeAlD
Gefitinib—SBK1—cerebellum—epilepsy syndrome	0.000684	0.0162	CbGeAlD
Gefitinib—CSNK1E—telencephalon—epilepsy syndrome	0.00068	0.0161	CbGeAlD
Gefitinib—ERBB3—telencephalon—epilepsy syndrome	0.000656	0.0156	CbGeAlD
Gefitinib—MKNK2—telencephalon—epilepsy syndrome	0.000624	0.0148	CbGeAlD
Gefitinib—IRAK1—telencephalon—epilepsy syndrome	0.000624	0.0148	CbGeAlD
Gefitinib—MKNK1—telencephalon—epilepsy syndrome	0.000616	0.0146	CbGeAlD
Gefitinib—EPHA6—head—epilepsy syndrome	0.000599	0.0142	CbGeAlD
Gefitinib—EPHA6—nervous system—epilepsy syndrome	0.000568	0.0135	CbGeAlD
Gefitinib—SBK1—brain—epilepsy syndrome	0.000556	0.0132	CbGeAlD
Gefitinib—HIPK4—brain—epilepsy syndrome	0.000549	0.013	CbGeAlD
Gefitinib—EPHA6—central nervous system—epilepsy syndrome	0.000547	0.013	CbGeAlD
Gefitinib—MAP3K19—head—epilepsy syndrome	0.000545	0.0129	CbGeAlD
Gefitinib—CSNK1E—medulla oblongata—epilepsy syndrome	0.000534	0.0127	CbGeAlD
Gefitinib—IRAK4—medulla oblongata—epilepsy syndrome	0.000526	0.0125	CbGeAlD
Gefitinib—MAP3K19—nervous system—epilepsy syndrome	0.000516	0.0123	CbGeAlD
Gefitinib—MAP2K5—brainstem—epilepsy syndrome	0.000511	0.0121	CbGeAlD
Gefitinib—MAP3K19—central nervous system—epilepsy syndrome	0.000497	0.0118	CbGeAlD
Gefitinib—MKNK2—medulla oblongata—epilepsy syndrome	0.00049	0.0116	CbGeAlD
Gefitinib—CSNK1E—midbrain—epilepsy syndrome	0.000488	0.0116	CbGeAlD
Gefitinib—MKNK1—medulla oblongata—epilepsy syndrome	0.000484	0.0115	CbGeAlD
Gefitinib—CHEK2—brain—epilepsy syndrome	0.000484	0.0115	CbGeAlD
Gefitinib—CSNK1E—spinal cord—epilepsy syndrome	0.000476	0.0113	CbGeAlD
Gefitinib—ERBB3—midbrain—epilepsy syndrome	0.000471	0.0112	CbGeAlD
Gefitinib—IRAK4—spinal cord—epilepsy syndrome	0.000469	0.0111	CbGeAlD
Gefitinib—Vandetanib—TYRO3—epilepsy syndrome	0.000467	0.0978	CrCbGaD
Gefitinib—ERBB3—spinal cord—epilepsy syndrome	0.00046	0.0109	CbGeAlD
Gefitinib—MAP2K5—telencephalon—epilepsy syndrome	0.000453	0.0108	CbGeAlD
Gefitinib—MKNK2—midbrain—epilepsy syndrome	0.000448	0.0106	CbGeAlD
Gefitinib—IRAK1—midbrain—epilepsy syndrome	0.000448	0.0106	CbGeAlD
Gefitinib—MKNK1—midbrain—epilepsy syndrome	0.000442	0.0105	CbGeAlD
Gefitinib—MKNK2—spinal cord—epilepsy syndrome	0.000437	0.0104	CbGeAlD
Gefitinib—Bosutinib—TYRO3—epilepsy syndrome	0.000437	0.0915	CrCbGaD
Gefitinib—EPHA6—brain—epilepsy syndrome	0.000434	0.0103	CbGeAlD
Gefitinib—MKNK1—spinal cord—epilepsy syndrome	0.000432	0.0102	CbGeAlD
Gefitinib—CSNK1E—head—epilepsy syndrome	0.000423	0.0101	CbGeAlD
Gefitinib—IRAK4—head—epilepsy syndrome	0.000417	0.0099	CbGeAlD
Gefitinib—ERBB3—head—epilepsy syndrome	0.000409	0.0097	CbGeAlD
Gefitinib—CSNK1E—nervous system—epilepsy syndrome	0.000401	0.00953	CbGeAlD
Gefitinib—IRAK4—nervous system—epilepsy syndrome	0.000395	0.00938	CbGeAlD
Gefitinib—MAP3K19—brain—epilepsy syndrome	0.000395	0.00937	CbGeAlD
Gefitinib—EGFR—cerebellum—epilepsy syndrome	0.000393	0.00933	CbGeAlD
Gefitinib—MKNK2—head—epilepsy syndrome	0.000389	0.00922	CbGeAlD
Gefitinib—ERBB3—nervous system—epilepsy syndrome	0.000387	0.0092	CbGeAlD
Gefitinib—CSNK1E—central nervous system—epilepsy syndrome	0.000387	0.00918	CbGeAlD
Gefitinib—MKNK1—head—epilepsy syndrome	0.000384	0.00911	CbGeAlD
Gefitinib—IRAK4—central nervous system—epilepsy syndrome	0.000381	0.00903	CbGeAlD
Gefitinib—CSNK1E—cerebellum—epilepsy syndrome	0.000378	0.00897	CbGeAlD
Gefitinib—ERBB3—central nervous system—epilepsy syndrome	0.000373	0.00885	CbGeAlD
Gefitinib—IRAK4—cerebellum—epilepsy syndrome	0.000372	0.00883	CbGeAlD
Gefitinib—MKNK2—nervous system—epilepsy syndrome	0.000368	0.00875	CbGeAlD
Gefitinib—ERBB3—cerebellum—epilepsy syndrome	0.000365	0.00865	CbGeAlD
Gefitinib—MKNK1—nervous system—epilepsy syndrome	0.000364	0.00864	CbGeAlD
Gefitinib—MAP2K5—medulla oblongata—epilepsy syndrome	0.000356	0.00845	CbGeAlD
Gefitinib—MKNK2—central nervous system—epilepsy syndrome	0.000355	0.00842	CbGeAlD
Gefitinib—Vandetanib—FYN—epilepsy syndrome	0.000354	0.0741	CrCbGaD
Gefitinib—MKNK1—central nervous system—epilepsy syndrome	0.00035	0.00831	CbGeAlD
Gefitinib—MKNK2—cerebellum—epilepsy syndrome	0.000347	0.00823	CbGeAlD
Gefitinib—IRAK1—cerebellum—epilepsy syndrome	0.000347	0.00823	CbGeAlD
Gefitinib—MKNK1—cerebellum—epilepsy syndrome	0.000342	0.00813	CbGeAlD
Gefitinib—Bosutinib—FYN—epilepsy syndrome	0.000331	0.0693	CrCbGaD
Gefitinib—MAP2K5—midbrain—epilepsy syndrome	0.000325	0.00772	CbGeAlD
Gefitinib—EGFR—brain—epilepsy syndrome	0.000319	0.00758	CbGeAlD
Gefitinib—MAP2K5—spinal cord—epilepsy syndrome	0.000317	0.00754	CbGeAlD
Gefitinib—STK10—head—epilepsy syndrome	0.000316	0.0075	CbGeAlD
Gefitinib—CSNK1E—brain—epilepsy syndrome	0.000307	0.00729	CbGeAlD
Gefitinib—IRAK4—brain—epilepsy syndrome	0.000302	0.00717	CbGeAlD
Gefitinib—STK10—nervous system—epilepsy syndrome	0.0003	0.00711	CbGeAlD
Gefitinib—CYP2D6—hindbrain—epilepsy syndrome	0.000297	0.00705	CbGeAlD
Gefitinib—ERBB3—brain—epilepsy syndrome	0.000296	0.00703	CbGeAlD
Gefitinib—STK10—central nervous system—epilepsy syndrome	0.000288	0.00685	CbGeAlD
Gefitinib—MAP2K5—head—epilepsy syndrome	0.000282	0.0067	CbGeAlD
Gefitinib—STK10—cerebellum—epilepsy syndrome	0.000282	0.00669	CbGeAlD
Gefitinib—MKNK2—brain—epilepsy syndrome	0.000282	0.00668	CbGeAlD
Gefitinib—IRAK1—brain—epilepsy syndrome	0.000282	0.00668	CbGeAlD
Gefitinib—Bosutinib—PTK2B—epilepsy syndrome	0.000281	0.0589	CrCbGaD
Gefitinib—MKNK1—brain—epilepsy syndrome	0.000278	0.0066	CbGeAlD
Gefitinib—Vandetanib—TEK—epilepsy syndrome	0.000275	0.0576	CrCbGaD
Gefitinib—MAP2K5—nervous system—epilepsy syndrome	0.000267	0.00635	CbGeAlD
Gefitinib—ORM1—spinal cord—epilepsy syndrome	0.000258	0.00612	CbGeAlD
Gefitinib—MAP2K5—central nervous system—epilepsy syndrome	0.000258	0.00611	CbGeAlD
Gefitinib—Vandetanib—RET—epilepsy syndrome	0.000256	0.0536	CrCbGaD
Gefitinib—MAP2K5—cerebellum—epilepsy syndrome	0.000252	0.00598	CbGeAlD
Gefitinib—STK10—brain—epilepsy syndrome	0.000229	0.00544	CbGeAlD
Gefitinib—ABCG2—telencephalon—epilepsy syndrome	0.00022	0.00523	CbGeAlD
Gefitinib—ORM1—nervous system—epilepsy syndrome	0.000217	0.00516	CbGeAlD
Gefitinib—ORM1—central nervous system—epilepsy syndrome	0.000209	0.00496	CbGeAlD
Gefitinib—MAP2K5—brain—epilepsy syndrome	0.000204	0.00485	CbGeAlD
Gefitinib—Minaprine—CHRM1—epilepsy syndrome	0.000198	0.0415	CrCbGaD
Gefitinib—ABCG2—medulla oblongata—epilepsy syndrome	0.000173	0.00411	CbGeAlD
Gefitinib—CYP2D6—brainstem—epilepsy syndrome	0.00017	0.00404	CbGeAlD
Gefitinib—Lapatinib—CYP2C19—epilepsy syndrome	0.000167	0.035	CrCbGaD
Gefitinib—CYP2D6—forebrain—epilepsy syndrome	0.000164	0.0039	CbGeAlD
Gefitinib—ABCG2—midbrain—epilepsy syndrome	0.000158	0.00376	CbGeAlD
Gefitinib—ABCG2—spinal cord—epilepsy syndrome	0.000154	0.00367	CbGeAlD
Gefitinib—CYP2D6—telencephalon—epilepsy syndrome	0.000151	0.00359	CbGeAlD
Gefitinib—Afatinib—ABCG2—epilepsy syndrome	0.000151	0.0316	CrCbGaD
Gefitinib—ALB—brain—epilepsy syndrome	0.000146	0.00346	CbGeAlD
Gefitinib—Vandetanib—SRC—epilepsy syndrome	0.000143	0.03	CrCbGaD
Gefitinib—Vandetanib—KDR—epilepsy syndrome	0.000134	0.0281	CrCbGaD
Gefitinib—Bosutinib—SRC—epilepsy syndrome	0.000134	0.028	CrCbGaD
Gefitinib—CYP1A1—head—epilepsy syndrome	0.00013	0.00309	CbGeAlD
Gefitinib—CYP1A1—nervous system—epilepsy syndrome	0.000124	0.00293	CbGeAlD
Gefitinib—ABCG2—cerebellum—epilepsy syndrome	0.000122	0.00291	CbGeAlD
Gefitinib—CYP1A1—central nervous system—epilepsy syndrome	0.000119	0.00282	CbGeAlD
Gefitinib—ABCB1—forebrain—epilepsy syndrome	0.000118	0.00281	CbGeAlD
Gefitinib—Iloperidone—HTR7—epilepsy syndrome	0.000117	0.0246	CrCbGaD
Gefitinib—Vandetanib—VEGFA—epilepsy syndrome	0.000114	0.0239	CrCbGaD
Gefitinib—ABCB1—telencephalon—epilepsy syndrome	0.000109	0.00258	CbGeAlD
Gefitinib—Erlotinib—ABCG2—epilepsy syndrome	0.000107	0.0223	CrCbGaD
Gefitinib—Minaprine—SLC6A4—epilepsy syndrome	0.000105	0.0221	CrCbGaD
Gefitinib—Iloperidone—ADRA2A—epilepsy syndrome	0.000101	0.0211	CrCbGaD
Gefitinib—ABCG2—brain—epilepsy syndrome	9.95e-05	0.00236	CbGeAlD
Gefitinib—CYP1A1—brain—epilepsy syndrome	9.44e-05	0.00224	CbGeAlD
Gefitinib—CYP2D6—head—epilepsy syndrome	9.41e-05	0.00223	CbGeAlD
Gefitinib—CYP3A4—nervous system—epilepsy syndrome	9.06e-05	0.00215	CbGeAlD
Gefitinib—CYP2D6—nervous system—epilepsy syndrome	8.92e-05	0.00212	CbGeAlD
Gefitinib—Lapatinib—ABCB1—epilepsy syndrome	8.86e-05	0.0186	CrCbGaD
Gefitinib—CYP3A4—central nervous system—epilepsy syndrome	8.73e-05	0.00207	CbGeAlD
Gefitinib—CYP2D6—central nervous system—epilepsy syndrome	8.59e-05	0.00204	CbGeAlD
Gefitinib—ABCB1—medulla oblongata—epilepsy syndrome	8.54e-05	0.00203	CbGeAlD
Gefitinib—CYP2D6—cerebellum—epilepsy syndrome	8.39e-05	0.00199	CbGeAlD
Gefitinib—Minaprine—HTR2A—epilepsy syndrome	8.09e-05	0.017	CrCbGaD
Gefitinib—Cisapride—CYP2C19—epilepsy syndrome	7.89e-05	0.0165	CrCbGaD
Gefitinib—ABCB1—midbrain—epilepsy syndrome	7.81e-05	0.00185	CbGeAlD
Gefitinib—ABCB1—spinal cord—epilepsy syndrome	7.62e-05	0.00181	CbGeAlD
Gefitinib—Minaprine—CYP2D6—epilepsy syndrome	7.4e-05	0.0155	CrCbGaD
Gefitinib—Vandetanib—ABCG2—epilepsy syndrome	7.02e-05	0.0147	CrCbGaD
Gefitinib—CYP2D6—brain—epilepsy syndrome	6.82e-05	0.00162	CbGeAlD
Gefitinib—ABCB1—head—epilepsy syndrome	6.77e-05	0.00161	CbGeAlD
Gefitinib—Infestation—Topiramate—epilepsy syndrome	6.51e-05	0.000451	CcSEcCtD
Gefitinib—Infestation NOS—Topiramate—epilepsy syndrome	6.51e-05	0.000451	CcSEcCtD
Gefitinib—Urticaria—Clonazepam—epilepsy syndrome	6.49e-05	0.00045	CcSEcCtD
Gefitinib—Eye disorder—Gabapentin—epilepsy syndrome	6.49e-05	0.000449	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Lamotrigine—epilepsy syndrome	6.47e-05	0.000448	CcSEcCtD
Gefitinib—Body temperature increased—Clonazepam—epilepsy syndrome	6.46e-05	0.000447	CcSEcCtD
Gefitinib—Abdominal pain—Clonazepam—epilepsy syndrome	6.46e-05	0.000447	CcSEcCtD
Gefitinib—Fatigue—Lamotrigine—epilepsy syndrome	6.46e-05	0.000447	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Topiramate—epilepsy syndrome	6.45e-05	0.000447	CcSEcCtD
Gefitinib—Urticaria—Phenytoin—epilepsy syndrome	6.45e-05	0.000447	CcSEcCtD
Gefitinib—Cardiac disorder—Gabapentin—epilepsy syndrome	6.45e-05	0.000446	CcSEcCtD
Gefitinib—Pruritus—Vigabatrin—epilepsy syndrome	6.43e-05	0.000445	CcSEcCtD
Gefitinib—Asthenia—Diazepam—epilepsy syndrome	6.42e-05	0.000445	CcSEcCtD
Gefitinib—Body temperature increased—Phenytoin—epilepsy syndrome	6.42e-05	0.000444	CcSEcCtD
Gefitinib—ABCB1—nervous system—epilepsy syndrome	6.42e-05	0.00152	CbGeAlD
Gefitinib—Urticaria—Oxcarbazepine—epilepsy syndrome	6.42e-05	0.000444	CcSEcCtD
Gefitinib—Constipation—Lamotrigine—epilepsy syndrome	6.4e-05	0.000443	CcSEcCtD
Gefitinib—Pain—Lamotrigine—epilepsy syndrome	6.4e-05	0.000443	CcSEcCtD
Gefitinib—Cisapride—HTR2A—epilepsy syndrome	6.4e-05	0.0134	CrCbGaD
Gefitinib—Nausea—Acetazolamide—epilepsy syndrome	6.4e-05	0.000443	CcSEcCtD
Gefitinib—Abdominal pain—Oxcarbazepine—epilepsy syndrome	6.38e-05	0.000442	CcSEcCtD
Gefitinib—Body temperature increased—Oxcarbazepine—epilepsy syndrome	6.38e-05	0.000442	CcSEcCtD
Gefitinib—Diarrhoea—Fosphenytoin—epilepsy syndrome	6.38e-05	0.000442	CcSEcCtD
Gefitinib—Cough—Valproic Acid—epilepsy syndrome	6.36e-05	0.000441	CcSEcCtD
Gefitinib—Vomiting—Propofol—epilepsy syndrome	6.36e-05	0.00044	CcSEcCtD
Gefitinib—Stomatitis—Topiramate—epilepsy syndrome	6.34e-05	0.000439	CcSEcCtD
Gefitinib—Gastrointestinal pain—Carbamazepine—epilepsy syndrome	6.34e-05	0.000439	CcSEcCtD
Gefitinib—Pruritus—Diazepam—epilepsy syndrome	6.33e-05	0.000438	CcSEcCtD
Gefitinib—Conjunctivitis—Topiramate—epilepsy syndrome	6.33e-05	0.000438	CcSEcCtD
Gefitinib—Rash—Propofol—epilepsy syndrome	6.31e-05	0.000437	CcSEcCtD
Gefitinib—Dermatitis—Propofol—epilepsy syndrome	6.3e-05	0.000436	CcSEcCtD
Gefitinib—Afatinib—ABCB1—epilepsy syndrome	6.28e-05	0.0132	CrCbGaD
Gefitinib—Mediastinal disorder—Gabapentin—epilepsy syndrome	6.26e-05	0.000433	CcSEcCtD
Gefitinib—Hypersensitivity—Zonisamide—epilepsy syndrome	6.25e-05	0.000433	CcSEcCtD
Gefitinib—Vomiting—Midazolam—epilepsy syndrome	6.22e-05	0.000431	CcSEcCtD
Gefitinib—Diarrhoea—Vigabatrin—epilepsy syndrome	6.22e-05	0.000431	CcSEcCtD
Gefitinib—Asthenia—Felbamate—epilepsy syndrome	6.22e-05	0.00043	CcSEcCtD
Gefitinib—Erlotinib—CYP2D6—epilepsy syndrome	6.21e-05	0.013	CrCbGaD
Gefitinib—Haematuria—Topiramate—epilepsy syndrome	6.21e-05	0.00043	CcSEcCtD
Gefitinib—ABCB1—central nervous system—epilepsy syndrome	6.18e-05	0.00147	CbGeAlD
Gefitinib—Rash—Midazolam—epilepsy syndrome	6.17e-05	0.000427	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	6.17e-05	0.000427	CcSEcCtD
Gefitinib—Dermatitis—Midazolam—epilepsy syndrome	6.17e-05	0.000427	CcSEcCtD
Gefitinib—Urticaria—Carbamazepine—epilepsy syndrome	6.16e-05	0.000426	CcSEcCtD
Gefitinib—Vomiting—Levetiracetam—epilepsy syndrome	6.15e-05	0.000425	CcSEcCtD
Gefitinib—Epistaxis—Topiramate—epilepsy syndrome	6.14e-05	0.000425	CcSEcCtD
Gefitinib—Alopecia—Gabapentin—epilepsy syndrome	6.14e-05	0.000425	CcSEcCtD
Gefitinib—Pruritus—Felbamate—epilepsy syndrome	6.13e-05	0.000424	CcSEcCtD
Gefitinib—Abdominal pain—Carbamazepine—epilepsy syndrome	6.13e-05	0.000424	CcSEcCtD
Gefitinib—Body temperature increased—Carbamazepine—epilepsy syndrome	6.13e-05	0.000424	CcSEcCtD
Gefitinib—Diarrhoea—Diazepam—epilepsy syndrome	6.12e-05	0.000424	CcSEcCtD
Gefitinib—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	6.12e-05	0.000424	CcSEcCtD
Gefitinib—Rash—Levetiracetam—epilepsy syndrome	6.09e-05	0.000422	CcSEcCtD
Gefitinib—Anaemia—Pregabalin—epilepsy syndrome	6.09e-05	0.000422	CcSEcCtD
Gefitinib—Dermatitis—Levetiracetam—epilepsy syndrome	6.09e-05	0.000422	CcSEcCtD
Gefitinib—Asthenia—Zonisamide—epilepsy syndrome	6.08e-05	0.000421	CcSEcCtD
Gefitinib—Dry mouth—Valproic Acid—epilepsy syndrome	6.07e-05	0.00042	CcSEcCtD
Gefitinib—Malnutrition—Gabapentin—epilepsy syndrome	6.05e-05	0.000419	CcSEcCtD
Gefitinib—ABCB1—cerebellum—epilepsy syndrome	6.04e-05	0.00143	CbGeAlD
Gefitinib—Angioedema—Pregabalin—epilepsy syndrome	6.02e-05	0.000417	CcSEcCtD
Gefitinib—Hypersensitivity—Clonazepam—epilepsy syndrome	6.02e-05	0.000417	CcSEcCtD
Gefitinib—Pruritus—Zonisamide—epilepsy syndrome	6e-05	0.000415	CcSEcCtD
Gefitinib—Hypersensitivity—Phenytoin—epilepsy syndrome	5.98e-05	0.000414	CcSEcCtD
Gefitinib—Urticaria—Lamotrigine—epilepsy syndrome	5.95e-05	0.000412	CcSEcCtD
Gefitinib—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	5.95e-05	0.000412	CcSEcCtD
Gefitinib—Malaise—Pregabalin—epilepsy syndrome	5.95e-05	0.000412	CcSEcCtD
Gefitinib—Nausea—Propofol—epilepsy syndrome	5.94e-05	0.000411	CcSEcCtD
Gefitinib—Vomiting—Fosphenytoin—epilepsy syndrome	5.93e-05	0.000411	CcSEcCtD
Gefitinib—Diarrhoea—Felbamate—epilepsy syndrome	5.93e-05	0.00041	CcSEcCtD
Gefitinib—Body temperature increased—Lamotrigine—epilepsy syndrome	5.92e-05	0.00041	CcSEcCtD
Gefitinib—Abdominal pain—Lamotrigine—epilepsy syndrome	5.92e-05	0.00041	CcSEcCtD
Gefitinib—Infection—Valproic Acid—epilepsy syndrome	5.91e-05	0.000409	CcSEcCtD
Gefitinib—Iloperidone—HTR2A—epilepsy syndrome	5.9e-05	0.0124	CrCbGaD
Gefitinib—Rash—Fosphenytoin—epilepsy syndrome	5.88e-05	0.000407	CcSEcCtD
Gefitinib—Dermatitis—Fosphenytoin—epilepsy syndrome	5.88e-05	0.000407	CcSEcCtD
Gefitinib—Haemoglobin—Topiramate—epilepsy syndrome	5.87e-05	0.000407	CcSEcCtD
Gefitinib—Asthenia—Clonazepam—epilepsy syndrome	5.86e-05	0.000406	CcSEcCtD
Gefitinib—Cisapride—CYP2D6—epilepsy syndrome	5.85e-05	0.0123	CrCbGaD
Gefitinib—Hepatitis—Topiramate—epilepsy syndrome	5.84e-05	0.000405	CcSEcCtD
Gefitinib—Haemorrhage—Topiramate—epilepsy syndrome	5.84e-05	0.000405	CcSEcCtD
Gefitinib—Nervous system disorder—Valproic Acid—epilepsy syndrome	5.84e-05	0.000404	CcSEcCtD
Gefitinib—Thrombocytopenia—Valproic Acid—epilepsy syndrome	5.83e-05	0.000403	CcSEcCtD
Gefitinib—Asthenia—Phenytoin—epilepsy syndrome	5.82e-05	0.000403	CcSEcCtD
Gefitinib—Nausea—Midazolam—epilepsy syndrome	5.81e-05	0.000403	CcSEcCtD
Gefitinib—Diarrhoea—Zonisamide—epilepsy syndrome	5.8e-05	0.000402	CcSEcCtD
Gefitinib—Asthenia—Oxcarbazepine—epilepsy syndrome	5.79e-05	0.000401	CcSEcCtD
Gefitinib—Pruritus—Clonazepam—epilepsy syndrome	5.78e-05	0.0004	CcSEcCtD
Gefitinib—Vomiting—Vigabatrin—epilepsy syndrome	5.78e-05	0.0004	CcSEcCtD
Gefitinib—Skin disorder—Valproic Acid—epilepsy syndrome	5.78e-05	0.0004	CcSEcCtD
Gefitinib—Urinary tract disorder—Topiramate—epilepsy syndrome	5.77e-05	0.000399	CcSEcCtD
Gefitinib—Oedema peripheral—Topiramate—epilepsy syndrome	5.76e-05	0.000398	CcSEcCtD
Gefitinib—Cough—Pregabalin—epilepsy syndrome	5.75e-05	0.000398	CcSEcCtD
Gefitinib—Pruritus—Phenytoin—epilepsy syndrome	5.74e-05	0.000398	CcSEcCtD
Gefitinib—Nausea—Levetiracetam—epilepsy syndrome	5.74e-05	0.000397	CcSEcCtD
Gefitinib—Rash—Vigabatrin—epilepsy syndrome	5.73e-05	0.000397	CcSEcCtD
Gefitinib—Dermatitis—Vigabatrin—epilepsy syndrome	5.73e-05	0.000397	CcSEcCtD
Gefitinib—Urethral disorder—Topiramate—epilepsy syndrome	5.73e-05	0.000397	CcSEcCtD
Gefitinib—Pruritus—Oxcarbazepine—epilepsy syndrome	5.71e-05	0.000396	CcSEcCtD
Gefitinib—Hypersensitivity—Carbamazepine—epilepsy syndrome	5.71e-05	0.000395	CcSEcCtD
Gefitinib—Vomiting—Diazepam—epilepsy syndrome	5.69e-05	0.000394	CcSEcCtD
Gefitinib—Anorexia—Valproic Acid—epilepsy syndrome	5.67e-05	0.000393	CcSEcCtD
Gefitinib—Rash—Diazepam—epilepsy syndrome	5.64e-05	0.000391	CcSEcCtD
Gefitinib—Dermatitis—Diazepam—epilepsy syndrome	5.64e-05	0.00039	CcSEcCtD
Gefitinib—Diarrhoea—Clonazepam—epilepsy syndrome	5.59e-05	0.000387	CcSEcCtD
Gefitinib—Anaemia—Gabapentin—epilepsy syndrome	5.59e-05	0.000387	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	5.57e-05	0.000386	CcSEcCtD
Gefitinib—Hypotension—Valproic Acid—epilepsy syndrome	5.56e-05	0.000385	CcSEcCtD
Gefitinib—Asthenia—Carbamazepine—epilepsy syndrome	5.56e-05	0.000385	CcSEcCtD
Gefitinib—Diarrhoea—Phenytoin—epilepsy syndrome	5.55e-05	0.000385	CcSEcCtD
Gefitinib—Nausea—Fosphenytoin—epilepsy syndrome	5.54e-05	0.000384	CcSEcCtD
Gefitinib—Diarrhoea—Oxcarbazepine—epilepsy syndrome	5.53e-05	0.000383	CcSEcCtD
Gefitinib—Erythema multiforme—Topiramate—epilepsy syndrome	5.52e-05	0.000382	CcSEcCtD
Gefitinib—Angioedema—Gabapentin—epilepsy syndrome	5.52e-05	0.000382	CcSEcCtD
Gefitinib—Hypersensitivity—Lamotrigine—epilepsy syndrome	5.52e-05	0.000382	CcSEcCtD
Gefitinib—Vomiting—Felbamate—epilepsy syndrome	5.51e-05	0.000381	CcSEcCtD
Gefitinib—Dry mouth—Pregabalin—epilepsy syndrome	5.49e-05	0.00038	CcSEcCtD
Gefitinib—Pruritus—Carbamazepine—epilepsy syndrome	5.48e-05	0.00038	CcSEcCtD
Gefitinib—Rash—Felbamate—epilepsy syndrome	5.46e-05	0.000378	CcSEcCtD
Gefitinib—Eye disorder—Topiramate—epilepsy syndrome	5.46e-05	0.000378	CcSEcCtD
Gefitinib—Dermatitis—Felbamate—epilepsy syndrome	5.46e-05	0.000378	CcSEcCtD
Gefitinib—Malaise—Gabapentin—epilepsy syndrome	5.45e-05	0.000377	CcSEcCtD
Gefitinib—Cardiac disorder—Topiramate—epilepsy syndrome	5.42e-05	0.000375	CcSEcCtD
Gefitinib—Nausea—Vigabatrin—epilepsy syndrome	5.4e-05	0.000374	CcSEcCtD
Gefitinib—Iloperidone—CYP2D6—epilepsy syndrome	5.4e-05	0.0113	CrCbGaD
Gefitinib—Vomiting—Zonisamide—epilepsy syndrome	5.39e-05	0.000373	CcSEcCtD
Gefitinib—Asthenia—Lamotrigine—epilepsy syndrome	5.37e-05	0.000372	CcSEcCtD
Gefitinib—Rash—Zonisamide—epilepsy syndrome	5.35e-05	0.00037	CcSEcCtD
Gefitinib—Infection—Pregabalin—epilepsy syndrome	5.35e-05	0.00037	CcSEcCtD
Gefitinib—Dermatitis—Zonisamide—epilepsy syndrome	5.34e-05	0.00037	CcSEcCtD
Gefitinib—Nausea—Diazepam—epilepsy syndrome	5.32e-05	0.000368	CcSEcCtD
Gefitinib—Dyspnoea—Valproic Acid—epilepsy syndrome	5.31e-05	0.000367	CcSEcCtD
Gefitinib—Diarrhoea—Carbamazepine—epilepsy syndrome	5.3e-05	0.000367	CcSEcCtD
Gefitinib—Angiopathy—Topiramate—epilepsy syndrome	5.3e-05	0.000367	CcSEcCtD
Gefitinib—Pruritus—Lamotrigine—epilepsy syndrome	5.3e-05	0.000367	CcSEcCtD
Gefitinib—Shock—Pregabalin—epilepsy syndrome	5.29e-05	0.000367	CcSEcCtD
Gefitinib—Nervous system disorder—Pregabalin—epilepsy syndrome	5.28e-05	0.000365	CcSEcCtD
Gefitinib—Cough—Gabapentin—epilepsy syndrome	5.28e-05	0.000365	CcSEcCtD
Gefitinib—Thrombocytopenia—Pregabalin—epilepsy syndrome	5.27e-05	0.000365	CcSEcCtD
Gefitinib—Mediastinal disorder—Topiramate—epilepsy syndrome	5.27e-05	0.000365	CcSEcCtD
Gefitinib—Skin disorder—Pregabalin—epilepsy syndrome	5.23e-05	0.000362	CcSEcCtD
Gefitinib—Vomiting—Clonazepam—epilepsy syndrome	5.2e-05	0.00036	CcSEcCtD
Gefitinib—Decreased appetite—Valproic Acid—epilepsy syndrome	5.17e-05	0.000358	CcSEcCtD
Gefitinib—Alopecia—Topiramate—epilepsy syndrome	5.16e-05	0.000357	CcSEcCtD
Gefitinib—Vomiting—Phenytoin—epilepsy syndrome	5.16e-05	0.000357	CcSEcCtD
Gefitinib—Rash—Clonazepam—epilepsy syndrome	5.15e-05	0.000357	CcSEcCtD
Gefitinib—Dermatitis—Clonazepam—epilepsy syndrome	5.15e-05	0.000356	CcSEcCtD
Gefitinib—Nausea—Felbamate—epilepsy syndrome	5.15e-05	0.000356	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	5.14e-05	0.000356	CcSEcCtD
Gefitinib—Vomiting—Oxcarbazepine—epilepsy syndrome	5.13e-05	0.000355	CcSEcCtD
Gefitinib—Fatigue—Valproic Acid—epilepsy syndrome	5.13e-05	0.000355	CcSEcCtD
Gefitinib—Anorexia—Pregabalin—epilepsy syndrome	5.13e-05	0.000355	CcSEcCtD
Gefitinib—Diarrhoea—Lamotrigine—epilepsy syndrome	5.12e-05	0.000355	CcSEcCtD
Gefitinib—Rash—Phenytoin—epilepsy syndrome	5.12e-05	0.000354	CcSEcCtD
Gefitinib—Dermatitis—Phenytoin—epilepsy syndrome	5.11e-05	0.000354	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	5.11e-05	0.000354	CcSEcCtD
Gefitinib—Rash—Oxcarbazepine—epilepsy syndrome	5.09e-05	0.000353	CcSEcCtD
Gefitinib—Pain—Valproic Acid—epilepsy syndrome	5.09e-05	0.000352	CcSEcCtD
Gefitinib—Constipation—Valproic Acid—epilepsy syndrome	5.09e-05	0.000352	CcSEcCtD
Gefitinib—Dermatitis—Oxcarbazepine—epilepsy syndrome	5.09e-05	0.000352	CcSEcCtD
Gefitinib—Malnutrition—Topiramate—epilepsy syndrome	5.09e-05	0.000352	CcSEcCtD
Gefitinib—Nausea—Zonisamide—epilepsy syndrome	5.04e-05	0.000349	CcSEcCtD
Gefitinib—Dry mouth—Gabapentin—epilepsy syndrome	5.03e-05	0.000348	CcSEcCtD
Gefitinib—Hypotension—Pregabalin—epilepsy syndrome	5.03e-05	0.000348	CcSEcCtD
Gefitinib—Vomiting—Carbamazepine—epilepsy syndrome	4.93e-05	0.000341	CcSEcCtD
Gefitinib—ABCB1—brain—epilepsy syndrome	4.9e-05	0.00116	CbGeAlD
Gefitinib—Infection—Gabapentin—epilepsy syndrome	4.9e-05	0.000339	CcSEcCtD
Gefitinib—Rash—Carbamazepine—epilepsy syndrome	4.89e-05	0.000338	CcSEcCtD
Gefitinib—Dermatitis—Carbamazepine—epilepsy syndrome	4.88e-05	0.000338	CcSEcCtD
Gefitinib—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	4.87e-05	0.000337	CcSEcCtD
Gefitinib—Nausea—Clonazepam—epilepsy syndrome	4.85e-05	0.000336	CcSEcCtD
Gefitinib—Shock—Gabapentin—epilepsy syndrome	4.85e-05	0.000336	CcSEcCtD
Gefitinib—Nervous system disorder—Gabapentin—epilepsy syndrome	4.84e-05	0.000335	CcSEcCtD
Gefitinib—Thrombocytopenia—Gabapentin—epilepsy syndrome	4.83e-05	0.000334	CcSEcCtD
Gefitinib—Nausea—Phenytoin—epilepsy syndrome	4.82e-05	0.000334	CcSEcCtD
Gefitinib—Dyspnoea—Pregabalin—epilepsy syndrome	4.8e-05	0.000332	CcSEcCtD
Gefitinib—Nausea—Oxcarbazepine—epilepsy syndrome	4.8e-05	0.000332	CcSEcCtD
Gefitinib—Skin disorder—Gabapentin—epilepsy syndrome	4.79e-05	0.000332	CcSEcCtD
Gefitinib—Vomiting—Lamotrigine—epilepsy syndrome	4.76e-05	0.00033	CcSEcCtD
Gefitinib—Urticaria—Valproic Acid—epilepsy syndrome	4.73e-05	0.000327	CcSEcCtD
Gefitinib—Rash—Lamotrigine—epilepsy syndrome	4.72e-05	0.000327	CcSEcCtD
Gefitinib—Dermatitis—Lamotrigine—epilepsy syndrome	4.72e-05	0.000327	CcSEcCtD
Gefitinib—Abdominal pain—Valproic Acid—epilepsy syndrome	4.7e-05	0.000326	CcSEcCtD
Gefitinib—Body temperature increased—Valproic Acid—epilepsy syndrome	4.7e-05	0.000326	CcSEcCtD
Gefitinib—Anorexia—Gabapentin—epilepsy syndrome	4.7e-05	0.000326	CcSEcCtD
Gefitinib—Anaemia—Topiramate—epilepsy syndrome	4.7e-05	0.000325	CcSEcCtD
Gefitinib—Decreased appetite—Pregabalin—epilepsy syndrome	4.68e-05	0.000324	CcSEcCtD
Gefitinib—Erlotinib—ALB—epilepsy syndrome	4.65e-05	0.00974	CrCbGaD
Gefitinib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	4.65e-05	0.000322	CcSEcCtD
Gefitinib—Fatigue—Pregabalin—epilepsy syndrome	4.64e-05	0.000321	CcSEcCtD
Gefitinib—Hypotension—Gabapentin—epilepsy syndrome	4.61e-05	0.000319	CcSEcCtD
Gefitinib—Nausea—Carbamazepine—epilepsy syndrome	4.6e-05	0.000319	CcSEcCtD
Gefitinib—Constipation—Pregabalin—epilepsy syndrome	4.6e-05	0.000319	CcSEcCtD
Gefitinib—Pain—Pregabalin—epilepsy syndrome	4.6e-05	0.000319	CcSEcCtD
Gefitinib—Malaise—Topiramate—epilepsy syndrome	4.59e-05	0.000318	CcSEcCtD
Gefitinib—Nausea—Lamotrigine—epilepsy syndrome	4.45e-05	0.000308	CcSEcCtD
Gefitinib—Cough—Topiramate—epilepsy syndrome	4.44e-05	0.000307	CcSEcCtD
Gefitinib—Erlotinib—ABCB1—epilepsy syndrome	4.44e-05	0.00929	CrCbGaD
Gefitinib—Gastrointestinal pain—Pregabalin—epilepsy syndrome	4.4e-05	0.000305	CcSEcCtD
Gefitinib—Dyspnoea—Gabapentin—epilepsy syndrome	4.4e-05	0.000305	CcSEcCtD
Gefitinib—Hypersensitivity—Valproic Acid—epilepsy syndrome	4.38e-05	0.000304	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	4.3e-05	0.000298	CcSEcCtD
Gefitinib—Decreased appetite—Gabapentin—epilepsy syndrome	4.29e-05	0.000297	CcSEcCtD
Gefitinib—Urticaria—Pregabalin—epilepsy syndrome	4.27e-05	0.000296	CcSEcCtD
Gefitinib—Asthenia—Valproic Acid—epilepsy syndrome	4.27e-05	0.000296	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	4.26e-05	0.000295	CcSEcCtD
Gefitinib—Fatigue—Gabapentin—epilepsy syndrome	4.25e-05	0.000295	CcSEcCtD
Gefitinib—Abdominal pain—Pregabalin—epilepsy syndrome	4.25e-05	0.000294	CcSEcCtD
Gefitinib—Body temperature increased—Pregabalin—epilepsy syndrome	4.25e-05	0.000294	CcSEcCtD
Gefitinib—Dry mouth—Topiramate—epilepsy syndrome	4.23e-05	0.000293	CcSEcCtD
Gefitinib—Pain—Gabapentin—epilepsy syndrome	4.22e-05	0.000292	CcSEcCtD
Gefitinib—Constipation—Gabapentin—epilepsy syndrome	4.22e-05	0.000292	CcSEcCtD
Gefitinib—Pruritus—Valproic Acid—epilepsy syndrome	4.21e-05	0.000292	CcSEcCtD
Gefitinib—Infection—Topiramate—epilepsy syndrome	4.12e-05	0.000286	CcSEcCtD
Gefitinib—Shock—Topiramate—epilepsy syndrome	4.08e-05	0.000283	CcSEcCtD
Gefitinib—Diarrhoea—Valproic Acid—epilepsy syndrome	4.07e-05	0.000282	CcSEcCtD
Gefitinib—Nervous system disorder—Topiramate—epilepsy syndrome	4.07e-05	0.000282	CcSEcCtD
Gefitinib—Thrombocytopenia—Topiramate—epilepsy syndrome	4.06e-05	0.000281	CcSEcCtD
Gefitinib—Gastrointestinal pain—Gabapentin—epilepsy syndrome	4.03e-05	0.000279	CcSEcCtD
Gefitinib—Skin disorder—Topiramate—epilepsy syndrome	4.03e-05	0.000279	CcSEcCtD
Gefitinib—Hypersensitivity—Pregabalin—epilepsy syndrome	3.96e-05	0.000274	CcSEcCtD
Gefitinib—Anorexia—Topiramate—epilepsy syndrome	3.96e-05	0.000274	CcSEcCtD
Gefitinib—Urticaria—Gabapentin—epilepsy syndrome	3.92e-05	0.000271	CcSEcCtD
Gefitinib—Abdominal pain—Gabapentin—epilepsy syndrome	3.9e-05	0.00027	CcSEcCtD
Gefitinib—Body temperature increased—Gabapentin—epilepsy syndrome	3.9e-05	0.00027	CcSEcCtD
Gefitinib—Hypotension—Topiramate—epilepsy syndrome	3.88e-05	0.000269	CcSEcCtD
Gefitinib—Asthenia—Pregabalin—epilepsy syndrome	3.86e-05	0.000267	CcSEcCtD
Gefitinib—Pruritus—Pregabalin—epilepsy syndrome	3.81e-05	0.000264	CcSEcCtD
Gefitinib—Vomiting—Valproic Acid—epilepsy syndrome	3.78e-05	0.000262	CcSEcCtD
Gefitinib—Rash—Valproic Acid—epilepsy syndrome	3.75e-05	0.00026	CcSEcCtD
Gefitinib—Dermatitis—Valproic Acid—epilepsy syndrome	3.75e-05	0.00026	CcSEcCtD
Gefitinib—Dyspnoea—Topiramate—epilepsy syndrome	3.7e-05	0.000256	CcSEcCtD
Gefitinib—Diarrhoea—Pregabalin—epilepsy syndrome	3.68e-05	0.000255	CcSEcCtD
Gefitinib—Hypersensitivity—Gabapentin—epilepsy syndrome	3.64e-05	0.000252	CcSEcCtD
Gefitinib—Decreased appetite—Topiramate—epilepsy syndrome	3.61e-05	0.00025	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	3.58e-05	0.000248	CcSEcCtD
Gefitinib—Fatigue—Topiramate—epilepsy syndrome	3.58e-05	0.000248	CcSEcCtD
Gefitinib—Constipation—Topiramate—epilepsy syndrome	3.55e-05	0.000246	CcSEcCtD
Gefitinib—Pain—Topiramate—epilepsy syndrome	3.55e-05	0.000246	CcSEcCtD
Gefitinib—Asthenia—Gabapentin—epilepsy syndrome	3.54e-05	0.000245	CcSEcCtD
Gefitinib—Nausea—Valproic Acid—epilepsy syndrome	3.54e-05	0.000245	CcSEcCtD
Gefitinib—Pruritus—Gabapentin—epilepsy syndrome	3.49e-05	0.000242	CcSEcCtD
Gefitinib—Vomiting—Pregabalin—epilepsy syndrome	3.42e-05	0.000237	CcSEcCtD
Gefitinib—Gastrointestinal pain—Topiramate—epilepsy syndrome	3.39e-05	0.000235	CcSEcCtD
Gefitinib—Rash—Pregabalin—epilepsy syndrome	3.39e-05	0.000235	CcSEcCtD
Gefitinib—Dermatitis—Pregabalin—epilepsy syndrome	3.39e-05	0.000235	CcSEcCtD
Gefitinib—Diarrhoea—Gabapentin—epilepsy syndrome	3.38e-05	0.000234	CcSEcCtD
Gefitinib—Urticaria—Topiramate—epilepsy syndrome	3.3e-05	0.000228	CcSEcCtD
Gefitinib—Abdominal pain—Topiramate—epilepsy syndrome	3.28e-05	0.000227	CcSEcCtD
Gefitinib—Body temperature increased—Topiramate—epilepsy syndrome	3.28e-05	0.000227	CcSEcCtD
Gefitinib—Nausea—Pregabalin—epilepsy syndrome	3.2e-05	0.000221	CcSEcCtD
Gefitinib—Vomiting—Gabapentin—epilepsy syndrome	3.14e-05	0.000217	CcSEcCtD
Gefitinib—Rash—Gabapentin—epilepsy syndrome	3.11e-05	0.000215	CcSEcCtD
Gefitinib—Dermatitis—Gabapentin—epilepsy syndrome	3.11e-05	0.000215	CcSEcCtD
Gefitinib—Vandetanib—ALB—epilepsy syndrome	3.06e-05	0.00641	CrCbGaD
Gefitinib—Hypersensitivity—Topiramate—epilepsy syndrome	3.06e-05	0.000212	CcSEcCtD
Gefitinib—Asthenia—Topiramate—epilepsy syndrome	2.98e-05	0.000206	CcSEcCtD
Gefitinib—Pruritus—Topiramate—epilepsy syndrome	2.94e-05	0.000203	CcSEcCtD
Gefitinib—Nausea—Gabapentin—epilepsy syndrome	2.93e-05	0.000203	CcSEcCtD
Gefitinib—Diarrhoea—Topiramate—epilepsy syndrome	2.84e-05	0.000197	CcSEcCtD
Gefitinib—Bosutinib—ABCB1—epilepsy syndrome	2.73e-05	0.00573	CrCbGaD
Gefitinib—Vomiting—Topiramate—epilepsy syndrome	2.64e-05	0.000183	CcSEcCtD
Gefitinib—Rash—Topiramate—epilepsy syndrome	2.62e-05	0.000181	CcSEcCtD
Gefitinib—Dermatitis—Topiramate—epilepsy syndrome	2.61e-05	0.000181	CcSEcCtD
Gefitinib—Nausea—Topiramate—epilepsy syndrome	2.47e-05	0.000171	CcSEcCtD
Gefitinib—EGFR—Immune System—CASP8—epilepsy syndrome	2.15e-06	2.09e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GPX1—epilepsy syndrome	2.15e-06	2.09e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	2.15e-06	2.09e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AVP—epilepsy syndrome	2.14e-06	2.08e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	2.14e-06	2.08e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MTOR—epilepsy syndrome	2.13e-06	2.07e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—POMC—epilepsy syndrome	2.13e-06	2.07e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—SRC—epilepsy syndrome	2.12e-06	2.06e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—VEGFA—epilepsy syndrome	2.11e-06	2.05e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—SLC2A1—epilepsy syndrome	2.1e-06	2.04e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—RELA—epilepsy syndrome	2.1e-06	2.04e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	2.09e-06	2.04e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALAD—epilepsy syndrome	2.09e-06	2.04e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NT5E—epilepsy syndrome	2.09e-06	2.04e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ADRA2A—epilepsy syndrome	2.09e-06	2.03e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCL2—epilepsy syndrome	2.08e-06	2.02e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—BCHE—epilepsy syndrome	2.08e-06	2.02e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PLCB1—epilepsy syndrome	2.08e-06	2.02e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—TH—epilepsy syndrome	2.07e-06	2.01e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MTOR—epilepsy syndrome	2.06e-06	2e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ABCG2—epilepsy syndrome	2.05e-06	2e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HES1—epilepsy syndrome	2.02e-06	1.97e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ABCG2—epilepsy syndrome	2e-06	1.95e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP2D6—epilepsy syndrome	2e-06	1.94e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	2e-06	1.94e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	2e-06	1.94e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP11A1—epilepsy syndrome	1.99e-06	1.93e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—AKT1—epilepsy syndrome	1.99e-06	1.93e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—SLC2A1—epilepsy syndrome	1.98e-06	1.93e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.97e-06	1.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FYN—epilepsy syndrome	1.97e-06	1.91e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PLCB1—epilepsy syndrome	1.96e-06	1.91e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CASP3—epilepsy syndrome	1.96e-06	1.91e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—H2AFX—epilepsy syndrome	1.96e-06	1.91e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MEF2C—epilepsy syndrome	1.96e-06	1.9e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	1.96e-06	1.9e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—TH—epilepsy syndrome	1.95e-06	1.9e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP2C19—epilepsy syndrome	1.95e-06	1.9e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—FGF2—epilepsy syndrome	1.94e-06	1.89e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP11A1—epilepsy syndrome	1.94e-06	1.89e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.92e-06	1.87e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—AKT1—epilepsy syndrome	1.92e-06	1.87e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ADSL—epilepsy syndrome	1.92e-06	1.86e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—JUN—epilepsy syndrome	1.9e-06	1.85e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ADRA2A—epilepsy syndrome	1.9e-06	1.85e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—BCHE—epilepsy syndrome	1.89e-06	1.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—YWHAZ—epilepsy syndrome	1.89e-06	1.84e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CASP3—epilepsy syndrome	1.89e-06	1.84e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	1.89e-06	1.84e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AGT—epilepsy syndrome	1.89e-06	1.83e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—FGF2—epilepsy syndrome	1.88e-06	1.83e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GLUL—epilepsy syndrome	1.88e-06	1.83e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	1.88e-06	1.83e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCG2—epilepsy syndrome	1.87e-06	1.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NGF—epilepsy syndrome	1.87e-06	1.82e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MMP9—epilepsy syndrome	1.85e-06	1.8e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	1.85e-06	1.8e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—APOE—epilepsy syndrome	1.85e-06	1.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—BCL2—epilepsy syndrome	1.85e-06	1.79e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	1.84e-06	1.79e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	1.84e-06	1.79e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—JUN—epilepsy syndrome	1.84e-06	1.79e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	1.83e-06	1.78e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP2C19—epilepsy syndrome	1.82e-06	1.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCR5—epilepsy syndrome	1.82e-06	1.77e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP11A1—epilepsy syndrome	1.81e-06	1.76e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—SLC2A1—epilepsy syndrome	1.81e-06	1.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—RELA—epilepsy syndrome	1.8e-06	1.75e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.8e-06	1.75e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.8e-06	1.75e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—FGF2—epilepsy syndrome	1.79e-06	1.75e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP2D6—epilepsy syndrome	1.79e-06	1.74e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PLCB1—epilepsy syndrome	1.79e-06	1.74e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MMP9—epilepsy syndrome	1.79e-06	1.74e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—TH—epilepsy syndrome	1.78e-06	1.73e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HTR2A—epilepsy syndrome	1.78e-06	1.73e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MTOR—epilepsy syndrome	1.77e-06	1.72e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.75e-06	1.71e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	1.75e-06	1.7e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—RELA—epilepsy syndrome	1.74e-06	1.7e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—AKT1—epilepsy syndrome	1.73e-06	1.68e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—HMOX1—epilepsy syndrome	1.73e-06	1.68e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	1.72e-06	1.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—AKT1—epilepsy syndrome	1.71e-06	1.67e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MTOR—epilepsy syndrome	1.71e-06	1.66e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SRC—epilepsy syndrome	1.71e-06	1.66e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ADRA2A—epilepsy syndrome	1.71e-06	1.66e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CAT—epilepsy syndrome	1.7e-06	1.66e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—BCHE—epilepsy syndrome	1.7e-06	1.65e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TSC2—epilepsy syndrome	1.69e-06	1.64e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AGT—epilepsy syndrome	1.69e-06	1.64e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AQP1—epilepsy syndrome	1.67e-06	1.63e-05	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.67e-06	1.62e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	1.67e-06	1.62e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—epilepsy syndrome	1.66e-06	1.62e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—BCHE—epilepsy syndrome	1.66e-06	1.61e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ABCB1—epilepsy syndrome	1.66e-06	1.61e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—APOE—epilepsy syndrome	1.65e-06	1.61e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SRC—epilepsy syndrome	1.65e-06	1.6e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.64e-06	1.6e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP2D6—epilepsy syndrome	1.64e-06	1.59e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MTOR—epilepsy syndrome	1.63e-06	1.59e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL1B—epilepsy syndrome	1.63e-06	1.59e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—HMOX1—epilepsy syndrome	1.63e-06	1.59e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—SLC2A1—epilepsy syndrome	1.62e-06	1.58e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KDR—epilepsy syndrome	1.62e-06	1.58e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—epilepsy syndrome	1.62e-06	1.57e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CAT—epilepsy syndrome	1.61e-06	1.56e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PLCB1—epilepsy syndrome	1.6e-06	1.56e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—epilepsy syndrome	1.6e-06	1.56e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—TH—epilepsy syndrome	1.6e-06	1.56e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—POMC—epilepsy syndrome	1.59e-06	1.54e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	1.58e-06	1.54e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—AKT1—epilepsy syndrome	1.58e-06	1.54e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—JUN—epilepsy syndrome	1.58e-06	1.54e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.57e-06	1.53e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CASP3—epilepsy syndrome	1.57e-06	1.53e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	1.57e-06	1.53e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PLCB1—epilepsy syndrome	1.57e-06	1.52e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ABCB1—epilepsy syndrome	1.57e-06	1.52e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—BCHE—epilepsy syndrome	1.56e-06	1.52e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—TH—epilepsy syndrome	1.56e-06	1.52e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PRKCB—epilepsy syndrome	1.56e-06	1.52e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—SRC—epilepsy syndrome	1.56e-06	1.52e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ADRA2A—epilepsy syndrome	1.56e-06	1.51e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6ST—epilepsy syndrome	1.55e-06	1.51e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—BCHE—epilepsy syndrome	1.55e-06	1.51e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GPX1—epilepsy syndrome	1.54e-06	1.5e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—JUN—epilepsy syndrome	1.53e-06	1.49e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—epilepsy syndrome	1.52e-06	1.48e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	1.51e-06	1.47e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	1.51e-06	1.47e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—AKT1—epilepsy syndrome	1.51e-06	1.47e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	1.49e-06	1.45e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—epilepsy syndrome	1.49e-06	1.45e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—HMOX1—epilepsy syndrome	1.49e-06	1.45e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SLC2A1—epilepsy syndrome	1.48e-06	1.44e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	1.48e-06	1.44e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—TH—epilepsy syndrome	1.47e-06	1.43e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CAT—epilepsy syndrome	1.47e-06	1.43e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PLCB1—epilepsy syndrome	1.46e-06	1.42e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—epilepsy syndrome	1.46e-06	1.42e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—TH—epilepsy syndrome	1.46e-06	1.42e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GPX1—epilepsy syndrome	1.46e-06	1.42e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—epilepsy syndrome	1.45e-06	1.41e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ALB—epilepsy syndrome	1.45e-06	1.41e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.44e-06	1.4e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ABCB1—epilepsy syndrome	1.43e-06	1.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—POMC—epilepsy syndrome	1.42e-06	1.38e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—SRC—epilepsy syndrome	1.42e-06	1.38e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL2—epilepsy syndrome	1.39e-06	1.35e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SRC—epilepsy syndrome	1.37e-06	1.33e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AGT—epilepsy syndrome	1.35e-06	1.31e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—epilepsy syndrome	1.34e-06	1.31e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—epilepsy syndrome	1.34e-06	1.3e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—HMOX1—epilepsy syndrome	1.33e-06	1.3e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GPX1—epilepsy syndrome	1.33e-06	1.29e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOE—epilepsy syndrome	1.32e-06	1.29e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—epilepsy syndrome	1.32e-06	1.28e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CAT—epilepsy syndrome	1.32e-06	1.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—SRC—epilepsy syndrome	1.31e-06	1.27e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HMOX1—epilepsy syndrome	1.3e-06	1.27e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CAT—epilepsy syndrome	1.29e-06	1.25e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ABCB1—epilepsy syndrome	1.28e-06	1.25e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AGT—epilepsy syndrome	1.28e-06	1.24e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—epilepsy syndrome	1.27e-06	1.23e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGF2—epilepsy syndrome	1.26e-06	1.22e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOE—epilepsy syndrome	1.25e-06	1.22e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	1.23e-06	1.2e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	1.23e-06	1.19e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HMOX1—epilepsy syndrome	1.22e-06	1.18e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CAT—epilepsy syndrome	1.21e-06	1.18e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	1.2e-06	1.17e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CAT—epilepsy syndrome	1.2e-06	1.17e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	1.2e-06	1.16e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GPX1—epilepsy syndrome	1.19e-06	1.16e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	1.18e-06	1.15e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ABCB1—epilepsy syndrome	1.17e-06	1.14e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RELA—epilepsy syndrome	1.17e-06	1.13e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AGT—epilepsy syndrome	1.16e-06	1.13e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GPX1—epilepsy syndrome	1.16e-06	1.13e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MTOR—epilepsy syndrome	1.14e-06	1.11e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOE—epilepsy syndrome	1.14e-06	1.11e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—POMC—epilepsy syndrome	1.14e-06	1.11e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GPX1—epilepsy syndrome	1.1e-06	1.07e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GPX1—epilepsy syndrome	1.09e-06	1.06e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	1.08e-06	1.05e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—POMC—epilepsy syndrome	1.07e-06	1.04e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—epilepsy syndrome	1.06e-06	1.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—epilepsy syndrome	1.05e-06	1.02e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AGT—epilepsy syndrome	1.04e-06	1.02e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ALB—epilepsy syndrome	1.04e-06	1.01e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	1.03e-06	9.99e-06	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—epilepsy syndrome	1.02e-06	9.95e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOE—epilepsy syndrome	1.02e-06	9.95e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—BCHE—epilepsy syndrome	1.02e-06	9.95e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—JUN—epilepsy syndrome	1.02e-06	9.94e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AGT—epilepsy syndrome	1.02e-06	9.91e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOE—epilepsy syndrome	9.99e-07	9.71e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—epilepsy syndrome	9.94e-07	9.67e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ALB—epilepsy syndrome	9.79e-07	9.52e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—POMC—epilepsy syndrome	9.79e-07	9.52e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	9.76e-07	9.49e-06	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—epilepsy syndrome	9.68e-07	9.41e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	9.65e-07	9.39e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—epilepsy syndrome	9.65e-07	9.38e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—TH—epilepsy syndrome	9.62e-07	9.35e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AGT—epilepsy syndrome	9.61e-07	9.34e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AGT—epilepsy syndrome	9.52e-07	9.26e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOE—epilepsy syndrome	9.41e-07	9.15e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOE—epilepsy syndrome	9.33e-07	9.07e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SRC—epilepsy syndrome	9.17e-07	8.92e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—epilepsy syndrome	9.07e-07	8.82e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—epilepsy syndrome	8.93e-07	8.68e-06	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—epilepsy syndrome	8.81e-07	8.57e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—POMC—epilepsy syndrome	8.79e-07	8.55e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—POMC—epilepsy syndrome	8.58e-07	8.34e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—epilepsy syndrome	8.57e-07	8.33e-06	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—epilepsy syndrome	8.52e-07	8.29e-06	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—epilepsy syndrome	8.14e-07	7.91e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—POMC—epilepsy syndrome	8.08e-07	7.86e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	8.03e-07	7.8e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—POMC—epilepsy syndrome	8.01e-07	7.79e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALB—epilepsy syndrome	8.01e-07	7.79e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CAT—epilepsy syndrome	7.92e-07	7.7e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALB—epilepsy syndrome	7.82e-07	7.61e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—epilepsy syndrome	7.81e-07	7.6e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	7.7e-07	7.49e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALB—epilepsy syndrome	7.37e-07	7.17e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALB—epilepsy syndrome	7.31e-07	7.11e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GPX1—epilepsy syndrome	7.16e-07	6.96e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—epilepsy syndrome	7.01e-07	6.82e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—epilepsy syndrome	6.84e-07	6.65e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	6.45e-07	6.27e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—epilepsy syndrome	6.39e-07	6.22e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—epilepsy syndrome	6.36e-07	6.19e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AGT—epilepsy syndrome	6.28e-07	6.11e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOE—epilepsy syndrome	6.15e-07	5.98e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—epilepsy syndrome	5.7e-07	5.54e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—POMC—epilepsy syndrome	5.29e-07	5.14e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALB—epilepsy syndrome	4.82e-07	4.69e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—epilepsy syndrome	4.56e-07	4.43e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—epilepsy syndrome	4.31e-07	4.19e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	4.22e-07	4.1e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—epilepsy syndrome	3.93e-07	3.82e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—epilepsy syndrome	3.52e-07	3.43e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—epilepsy syndrome	3.44e-07	3.34e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—epilepsy syndrome	3.24e-07	3.15e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—epilepsy syndrome	3.21e-07	3.12e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—epilepsy syndrome	2.12e-07	2.06e-06	CbGpPWpGaD
